Takeda and Fujifilm to develop new heart failure therapies

Pharmaceutical Company Product News

Takeda has announced a new collaboration with Fujifilm that will focus on the development of a new line of innovative regenerative medicine therapies.

These new drugs will use cardiomyocytes derived from induced pluripotent stem cells (iPSC) for the treatment of heart failure, leveraging both companies' experience to ensure that high-quality cells can be manufactured safely and efficiently.

“Takeda is partnering with Fujifilm on the development of new regenerative medicine therapies for the treatment of heart failure.“

Specifically, Fujifilm will contribute its expertise in cutting-edge iPSC-related technologies and engineering capabilities, nurtured through its photographic business, along with Takeda's iPSC technology expertise.

The companies will also partner with the Center for iPS Cell Research and Application at Kyoto University, which will deliver assistance with any preclinical and clinical studies carried out as part of this drug development collaboration.

Dr Seigo Izumo, global head of the regenerative medicine unit at Takeda, said: "This collaboration allows us to leverage the strengths of both organisations with the goal of achieving meaningful, life-changing benefits for patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news